Baker Bros. Advisors LP Rhythm Pharmaceuticals, Inc. Transaction History
Baker Bros. Advisors LP
- $7.52 Billion
- Q2 2024
A detailed history of Baker Bros. Advisors LP transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 6,398,365 shares of RYTM stock, worth $315 Million. This represents 3.49% of its overall portfolio holdings.
Number of Shares
6,398,365
Previous 6,398,365
-0.0%
Holding current value
$315 Million
Previous $277 Million
5.24%
% of portfolio
3.49%
Previous 3.51%
Shares
13 transactions
Others Institutions Holding RYTM
# of Institutions
178Shares Held
69.1MCall Options Held
467KPut Options Held
224K-
Primecap Management CO Pasadena, CA7.31MShares$360 Million0.22% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$332 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$300 Million3.77% of portfolio
-
Goldman Sachs Group Inc New York, NY5.29MShares$260 Million0.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.45MShares$170 Million4.09% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $2.74B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...